Biocon Biologics Ltd (BBL), a leading biosimilars company and subsidiary of Biocon Ltd (BSE code: 532523, NSE: BIOCON), has announced a significant five-ye...
In a strategic shift that promises to redefine the pharmaceutical industry, Novo Holdings, the investment arm of Novo Nordisk's parent foundation, has unve...
Tyruko® approved for all indications of reference medicine Tyruko® biosimilar to treat adults with highly active relapsing remitting multi...
Glenmark will be responsible for further developing, registering, and commercializing Envafolimab in India, Asia Pacific, Middle East...
Zurletrectinib, developed by InnoCare, is a pan-TRK inhibitor which markedly inhibits the activity of the wild type TRKA, TRKB and TRKC, as well as mutant ...
“The closing of the Mirati transaction is a significant milestone in our efforts to further diversify our oncology portfolio and strengthen our pipel...
Maureen Deehan, CEO of Vivtex, commented: “We are delighted to enter this new collaboration with Astellas Pharma. Over the past few years, Vivtex has...
Glass vials are regularly used for pharmaceutical packaging, though there is a growing market need for primary packaging that is suited to more sensitive, ...
BioPharma BoardRoom sat down with Simona Grandits, Senior Director, Head of Sales and Marketing EEMEA at QIAGEN, to delve into the company's recent strateg...
“We are very excited that our partner is moving forward with licensing the XeriJect technology to further the development of the XeriJect subcutaneou...
Underpinning this objective Rousseau outlines the investment achievements already notched up in 2023, to illustrate how SGD Pharma has paved the way for th...
Ovarian cancer data supports registration-enabling trial of luvelta for women with platinum-resistant ovarian cancer Potential benefit to 8 out of 10 plat...
Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company dedicated to the development and commercial...
-- Phase 1 dose escalation study in patients with MAPK pathway driven advanced solid tumors to begin in Q1 2024 – -- Initial readout expected as ear...
© 2025 Biopharma Boardroom. All Rights Reserved.
